I've spoken to JChick about this now. He's re-iterated that the Immunotherapies arm has "sufficient capital" for the Head and Neck study and ongoing activities but will seek other options regarding funding. He "doesn't see" the vax arm being funded from the Admedus balance sheet in the future.
Also covered: Divestment still possible, but would have to come with investment into the immunotherapies business. Where that investment would come from is currently a mystery.
"Take a Closer Look", page-848
-
- There are more pages in this discussion • 380 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |